Free Trial
OTCMKTS:ELTP

Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Elite Pharmaceuticals logo
$0.60 0.00 (-0.15%)
As of 12:59 PM Eastern

About Elite Pharmaceuticals Stock (OTCMKTS:ELTP)

Key Stats

Today's Range
$0.57
$0.60
50-Day Range
$0.41
$0.77
52-Week Range
$0.16
$0.82
Volume
1.51 million shs
Average Volume
1.24 million shs
Market Capitalization
$639.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elite Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

ELTP MarketRank™: 

Elite Pharmaceuticals scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Elite Pharmaceuticals.

  • Percentage of Shares Shorted

    0.25% of the float of Elite Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elite Pharmaceuticals has recently increased by 1.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Elite Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Elite Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.25% of the float of Elite Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elite Pharmaceuticals has recently increased by 1.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Elite Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Elite Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    4 people have searched for ELTP on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.01% of the stock of Elite Pharmaceuticals is held by institutions.

  • Read more about Elite Pharmaceuticals' insider trading history.
Receive ELTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELTP Stock News Headlines

Here's the last trade you should make before heading out for the weekend tomorrow.
Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.
Elite Pharmaceuticals, Inc. (ELTP) - Yahoo Finance
Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse
See More Headlines

ELTP Stock Analysis - Frequently Asked Questions

Elite Pharmaceuticals' stock was trading at $0.5411 at the start of the year. Since then, ELTP shares have increased by 10.7% and is now trading at $0.5989.
View the best growth stocks for 2025 here
.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) posted its quarterly earnings results on Monday, June, 30th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The specialty pharmaceutical company had revenue of $32 million for the quarter. Elite Pharmaceuticals had a negative net margin of 25.70% and a negative trailing twelve-month return on equity of 6.92%.
Read the conference call transcript
.

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
6/30/2025
Today
7/03/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ELTP
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$20.11 million
Pretax Margin
-24.76%

Debt

Sales & Book Value

Annual Sales
$84.04 million
Cash Flow
$0.02 per share
Price / Cash Flow
39.12
Book Value
$0.05 per share
Price / Book
11.98

Miscellaneous

Outstanding Shares
1,068,360,000
Free Float
914,305,000
Market Cap
$639.84 million
Optionable
Not Optionable
Beta
0.25
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:ELTP) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners